» Articles » PMID: 33554891

Investigation of Transcriptome Profile of Ischemia/reperfusion Injury of Abdominal Skin Flaps in Rats After Methane-rich Saline Treatment Using RNA-seq

Overview
Publisher Sage Publications
Date 2021 Feb 8
PMID 33554891
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Here we examined the influence of methane-rich saline treatment (MS) on the whole transcriptome of the skin flaps during the ischemia/reperfusion (I/R) injuryusing RNA-sequence (RNA-seq).

Methods: The rats were divided into three groups: the sham surgery group (SH),the I/R surgery group treated with physiological saline (I/R-P) or the I/R surgery group treated with the methane-rich saline (I/R-M) respectively. On the 72 hours after operation, the perfusion and the distribution of micro-circulatoryblood flow in skin flaps were observed by laser doppler flowmeters. The whole transcriptome alteration of the skin flaps was examined using RNA-seq. Moreover, the responses of the skin flaps to MRS treatment were examined using bio-informatic and q-PCR approaches after I/R injury.

Results: The methane-rich saline (MS) treatment could expand survival area and improve the blood perfusion of the skin flaps after l/R injury. Compared to the I/R-P group, 474 genes significantly altered in the I/R-M group. These genes were mainly associated the development, the cell adhesion and migration. In addition, the PI3K-Akt signal pathway was meaningfully related to regulation of MS treatment. Q-PCR results confirmed that MS treatment positively regulated PI3K-Akt signal pathway relative genes and inhibited the cell adhesion relative genes.

Conclusion: These results proved that methane-rich saline may alleviate I/R injury and improve flap survival rate by regulating cell adhesion and PI3K-Akt signal pathway.

Citing Articles

Exploration of the Protective Mechanism of Bax Removal against Ischemia Reperfusion Injury of Skin Flap through the p38 Mitogen-Activated Protein Kinase Pathway.

Wang Y, Wu Y, Wang P, Luo J, Rui Y Oxid Med Cell Longev. 2022; 2022:1175078.

PMID: 36299606 PMC: 9592197. DOI: 10.1155/2022/1175078.